94 related articles for article (PubMed ID: 12208412)
21. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study.
Mäkinen K; Manninen H; Hedman M; Matsi P; Mussalo H; Alhava E; Ylä-Herttuala S
Mol Ther; 2002 Jul; 6(1):127-33. PubMed ID: 12095313
[TBL] [Abstract][Full Text] [Related]
22. VEGF gene transfer for diabetic neuropathy.
Isner JM; Ropper A; Hirst K
Hum Gene Ther; 2001 Aug; 12(12):1593-4. PubMed ID: 11529248
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial.
Lederman RJ; Mendelsohn FO; Anderson RD; Saucedo JF; Tenaglia AN; Hermiller JB; Hillegass WB; Rocha-Singh K; Moon TE; Whitehouse MJ; Annex BH;
Lancet; 2002 Jun; 359(9323):2053-8. PubMed ID: 12086757
[TBL] [Abstract][Full Text] [Related]
24. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
Ben-Gary H; McKinney RL; Rosengart T; Lesser ML; Crystal RG
Mol Ther; 2002 Aug; 6(2):287-97. PubMed ID: 12349828
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ.
Vajanto I; Rissanen TT; Rutanen J; Hiltunen MO; Tuomisto TT; Arve K; Närvänen O; Manninen H; Räsänen H; Hippeläinen M; Alhava E; Ylä-Herttuala S
J Gene Med; 2002; 4(4):371-80. PubMed ID: 12124979
[TBL] [Abstract][Full Text] [Related]
26. Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication.
Ahimastos AA; Latouche C; Natoli AK; Reddy-luthmoodoo M; Golledge J; Kingwell BA
Circ Res; 2014 Mar; 114(7):1144-55. PubMed ID: 24397981
[TBL] [Abstract][Full Text] [Related]
27. Effect of Bosentan on Claudication Distance and Endothelium-Dependent Vasodilation in Hispanic Patients With Peripheral Arterial Disease.
De Haro J; Bleda S; Varela C; Esparza L; Acin F;
Am J Cardiol; 2016 Jan; 117(2):295-301. PubMed ID: 26651453
[TBL] [Abstract][Full Text] [Related]
28. Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis.
Lazarous DF; Shou M; Stiber JA; Hodge E; Thirumurti V; Gonçalves L; Unger EF
Cardiovasc Res; 1999 Nov; 44(2):294-302. PubMed ID: 10690306
[TBL] [Abstract][Full Text] [Related]
29. Smoking Habits of Patients Undergoing Treatment for Intermittent Claudication in the Vascular Quality Initiative.
Gabel J; Jabo B; Patel S; Kiang S; Bianchi C; Chiriano J; Teruya T; Abou-Zamzam AM;
Ann Vasc Surg; 2017 Oct; 44():261-268. PubMed ID: 28522329
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of transcutaneous electrical nerve stimulation on the improvement of walking distance in patients with peripheral arterial disease with intermittent claudication: study protocol for a randomised controlled trial: the TENS-PAD study.
Besnier F; Sénard JM; Grémeaux V; Riédel M; Garrigues D; Guiraud T; Labrunée M
Trials; 2017 Aug; 18(1):373. PubMed ID: 28797281
[TBL] [Abstract][Full Text] [Related]
31. Intraventricular infusion of vascular endothelial growth factor promotes cerebral angiogenesis with minimal brain edema.
Harrigan MR; Ennis SR; Masada T; Keep RF
Neurosurgery; 2002 Mar; 50(3):589-98. PubMed ID: 11841728
[TBL] [Abstract][Full Text] [Related]
32. Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy.
Hiatt WR; Hirsch AT; Cooke JP; Olin JW; Brater DC; Creager MA
Vasc Med; 2004 Feb; 9(1):18-25. PubMed ID: 15230484
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease.
Rosengart TK; Bishawi MM; Halbreiner MS; Fakhoury M; Finnin E; Hollmann C; Shroyer AL; Crystal RG
Hum Gene Ther; 2013 Feb; 24(2):203-8. PubMed ID: 23137122
[TBL] [Abstract][Full Text] [Related]
34. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. Journal of the American Medical Association 2013; 309: 453-460.
Kurklinsky AK; Levy M
Vasc Med; 2013 Aug; 18(4):234-6. PubMed ID: 23867841
[TBL] [Abstract][Full Text] [Related]
35. Adenovirus vector-mediated transfer of the vascular endothelial growth factor cDNA to healing abdominal fascia enhances vascularity and bursting strength in mice with normal and impaired wound healing.
Ailawadi M; Lee JM; Lee S; Hackett N; Crystal RG; Korst RJ
Surgery; 2002 Feb; 131(2):219-27. PubMed ID: 11854705
[TBL] [Abstract][Full Text] [Related]
36. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Hiatt WR; Money SR; Brass EP
J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
[TBL] [Abstract][Full Text] [Related]
37. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication.
Luo T; Li J; Li L; Yang B; Liu C; Zheng Q; Jin B; Chen Z; Li K; Zhang X; Zhang J
Thromb Res; 2013 Oct; 132(4):427-32. PubMed ID: 23998557
[TBL] [Abstract][Full Text] [Related]
38. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia.
Takeshita S; Pu LQ; Stein LA; Sniderman AD; Bunting S; Ferrara N; Isner JM; Symes JF
Circulation; 1994 Nov; 90(5 Pt 2):II228-34. PubMed ID: 7525111
[TBL] [Abstract][Full Text] [Related]
39. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
[TBL] [Abstract][Full Text] [Related]
40. Local perivascular application of low amounts of a plasmid encoding for vascular endothelial growth factor (VEGF165) is efficient for therapeutic angiogenesis in pigs.
Nikol S; Engelmann MG; Pelisek J; Fuchs A; Golda A; Shimizu M; Mekkaoui C; Rolland PH
Acta Physiol Scand; 2002 Oct; 176(2):151-9. PubMed ID: 12354175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
